Evaluation of the effect of oral Allopurinol on liver function test in childhood leukemia in maintenance therapy phase

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190107042281N1

Enrollment

Registered

2019-08-20

Start date

2019-06-01

Completion date

Unknown

Last updated

2019-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute lymphoblastic leukemia. Acute lymphoblastic leukemia [ALL]

Interventions

Intervention 1: Intervention group: Allopurinol tablet receive 4 mg /kg/ day and up to 200 mg daily, divided into two doses. Intervention 2: Control group: There is no intervention.

Eligibility

Sex/Gender

All

Age

2 Years to 15 Years

Inclusion criteria

Inclusion criteria: Children with acute lymphocytic leukemia treated with mercaptopurine

Exclusion criteria

Exclusion criteria: Parental dissatisfaction Renal failure Hepatitis B Hepatitis C AIDS

Design outcomes

Primary

Measure	Time frame
Alanine Aminotransferase. Timepoint: Measurement of serum Alanine Aminotransferase (ALT) levels At the beginning of the study and 1, 2, 3, 4, 5 and 6 months after initiation of allopurinol administration. Method of measurement: blood test.;Aspartate Aminotransferase. Timepoint: Measurement of serum Aspartate Aminotransferase (AST) levels at the beginning of the study and 1, 2, 3, 4, 5 and 6 months after initiation of allopurinol administration. Method of measurement: blood test.;Alkaline Phosphatase. Timepoint: Measurement of serum Alkaline Phosphatase (ALP) levels at the beginning of the study and 1, 2, 3, 4, 5 and 6 months after initiation of allopurinol administration. Method of measurement: blood test.;Total Bilirubin. Timepoint: Measurement of serum Total Bilirubin levels at the beginning of the study and 1, 2, 3, 4, 5 and 6 months after initiation of allopurinol administration. Method of measurement: blood test.;Direct Bilirubin. Timepoint: Measurement of serum Direct Bilirubin levels at the beginning of the study and 1, 2, 3, 4, 5 and 6 months after initiation of allopurinol administration. Method of measurement: blood test.	—

Measure

Time frame

Alanine Aminotransferase. Timepoint: Measurement of serum Alanine Aminotransferase (ALT) levels At the beginning of the study and 1, 2, 3, 4, 5 and 6 months after initiation of allopurinol administration. Method of measurement: blood test.;Aspartate Aminotransferase. Timepoint: Measurement of serum Aspartate Aminotransferase (AST) levels at the beginning of the study and 1, 2, 3, 4, 5 and 6 months after initiation of allopurinol administration. Method of measurement: blood test.;Alkaline Phosphatase. Timepoint: Measurement of serum Alkaline Phosphatase (ALP) levels at the beginning of the study and 1, 2, 3, 4, 5 and 6 months after initiation of allopurinol administration. Method of measurement: blood test.;Total Bilirubin. Timepoint: Measurement of serum Total Bilirubin levels at the beginning of the study and 1, 2, 3, 4, 5 and 6 months after initiation of allopurinol administration. Method of measurement: blood test.;Direct Bilirubin. Timepoint: Measurement of serum Direct Bilirubin levels at the beginning of the study and 1, 2, 3, 4, 5 and 6 months after initiation of allopurinol administration. Method of measurement: blood test.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactRoya Shaykh Baygloo

Arak University of Medical Sciences

royashb@yahoo.com+98 863313471519

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026